{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:34:55Z","timestamp":1788194095872,"version":"build-2803163510"},"reference-count":60,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapeutics and Clinical Risk Management"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.2147\/tcrm.2007.3.2.309","type":"journal-article","created":{"date-parts":[[2007,5,27]],"date-time":"2007-05-27T21:05:01Z","timestamp":1180299901000},"page":"309-317","source":"Crossref","is-referenced-by-count":41,"title":["Skin and skin structure infections: treatment with newer generation fluoroquinolones"],"prefix":"10.2147","volume":"3","author":[{"given":"Philip","family":"Giordano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Gesin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Kubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","reference":[{"key":"p_1_271","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2003.11.376"},{"key":"p_2_272","doi-asserted-by":"publisher","DOI":"10.1086\/498520"},{"key":"p_3_273","unstructured":"[AMR] Arlington Medical Resources. 2004. Hospital Antibiotic Market Database [online]. Accessed on 25 July 2006. URL: http:\/\/www.amr-data.com\/."},{"key":"p_4_274","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(04)90170-1"},{"key":"p_5_275","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/45.5.557"},{"key":"p_6_276","unstructured":"Bayer Pharmaceuticals Co. 2005. Avelox (moxifloxacin) package insert. Westhaven, CT: Bayer Pharmaceuticals."},{"key":"p_7_277","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-6701(98)90019-6"},{"key":"p_8_278","doi-asserted-by":"publisher","DOI":"10.1086\/339075"},{"key":"p_9_279","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(03)00092-X"},{"key":"p_10_280","unstructured":"Bristol-Myers Squibb Co. 2006a. Tequin (gatifloxacin) package insert. Princeton, NJ: Bristol-Myers Squibb Co."},{"key":"p_11_281","unstructured":"Bristol-Myers Squibb Co. 2006b. Dear Health Care Provider letter [online]. Accessed 10 April 2006. URL: www.fda.gov\/medWatch\/safety\/2006\/ tequin_DHCP.pdf."},{"key":"p_12_282","first-page":"381","volume":"50","author":"Center","year":"2001","journal-title":"San Francisco General Hospital--1996-2000. MMWR"},{"key":"p_13_283","unstructured":"[CLSI] Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial susceptibility testing. Sixteenth Informational Supplement. CLSI document M100-S16."},{"key":"p_14_284","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.1040876"},{"key":"p_15_285","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh202"},{"key":"p_16_286","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.3.1012-1016.2004"},{"key":"p_17_287","unstructured":"[EMEA] European Agency for the Evaluation of Medicinal Products; Committee for Proprietary Medicinal Products. 2006. Points to consider: the assessment of the potential for QT interval prolongation by noncardiovascular medicinal products [online]. Accessed 10 April 2006. URL: www.coresearch.biz\/regulations\/cpmp.pdf."},{"key":"p_18_288","unstructured":"[FDA] Food and Drug Administration. 1998. Guidance for industry: uncomplicated skin and skin structure infections-Developing antimicrobial drugs for therapy [online]. Accessed 10 April 2005. URL: www.fda.gov\/cder\/guidance\/2566dft.pdf."},{"key":"p_19_289","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.10.4740-4744.2003"},{"key":"p_20_290","unstructured":"File TM Jr. Tan JS. 1995. Treatment of skin and soft-tissue infections. Am J Surgery, 169(5A Suppl):27S-33S."},{"key":"p_21_291","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.7.2642-2647.2005"},{"key":"p_22_292","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.37.5.1073","volume":"37","author":"Forrest A","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"p_23_293","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2004.10.011"},{"key":"p_24_294","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg035"},{"key":"p_25_295","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1093\/ajhp\/60.23.2479","volume":"60","author":"Gandhi PJ","year":"2003","journal-title":"Am J Health-Syst Pharm"},{"key":"p_26_296","doi-asserted-by":"publisher","DOI":"10.1086\/382084"},{"key":"p_27_297","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2005.07.017"},{"key":"p_28_298","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf009"},{"key":"p_29_299","doi-asserted-by":"publisher","DOI":"10.1086\/341026"},{"key":"p_30_300","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.4.8.1259"},{"key":"p_31_301","doi-asserted-by":"publisher","DOI":"10.1254\/jjp.87.231"},{"key":"p_32_302","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.3.361.34204"},{"key":"p_33_303","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1086\/520276","volume":"26","author":"Johnson S","year":"1998","journal-title":"Clin Infect Dis"},{"key":"p_34_304","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000109288.06912.21"},{"key":"p_35_305","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051639"},{"key":"p_36_306","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.10.2600-2603.2000"},{"key":"p_37_307","doi-asserted-by":"publisher","DOI":"10.1007\/s001340050770"},{"key":"p_38_308","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.4.1102-1107.2000"},{"key":"p_39_309","doi-asserted-by":"crossref","first-page":"S239","DOI":"10.1093\/clinids\/16.Supplement_4.S239","volume":"16","author":"Mulligan ME","year":"1993","journal-title":"Clin Infect Dis."},{"key":"p_40_310","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.22.2976"},{"key":"p_41_311","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1097\/00007611-199712000-00006","volume":"90","author":"Nichols RL","year":"1997","journal-title":"South Med J"},{"key":"p_42_312","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.suppl_1.19"},{"key":"p_43_313","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.10.4234-4239.2005"},{"key":"p_44_314","unstructured":"Ortho-McNeil Pharmaceutical. 2005. Levaquin (levofloxacin) package insert. Raritan, NJ."},{"key":"p_45_315","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.3.301.34206"},{"key":"p_46_316","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464100-00005"},{"key":"p_47_317","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.3.299"},{"key":"p_48_318","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1742-1241.2000.tb10911.x","volume":"54","author":"Parish LC","year":"2000","journal-title":"Int J Clin Pract"},{"key":"p_49_319","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464150-00002"},{"key":"p_50_320","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(02)00543-6"},{"key":"p_51_321","doi-asserted-by":"publisher","DOI":"10.1086\/497143"},{"key":"p_52_322","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.8.2358-2362.2001"},{"key":"p_53_323","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.11.3630-3633.2002"},{"key":"p_54_324","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.5.1352-1355.2000"},{"key":"p_55_325","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3201\/eid0911.030284","volume":"9","author":"Weber SG","year":"2003","journal-title":"Emerg Infect Dis"},{"key":"p_56_326","unstructured":"Wickersham RM, Schweain SL (eds). 2005. Drug facts and comparisons. St. Louis: Wolters Kluwer Health, Inc."},{"key":"p_57_327","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1128\/AAC.43.6.1508","volume":"43","author":"Wise R","year":"1999","journal-title":"Antimicrob Agents and Chemother"},{"key":"p_58_328","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/46.5.669"},{"key":"p_59_329","doi-asserted-by":"publisher","DOI":"10.1136\/heart.89.11.1363"},{"key":"p_60_330","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2005.6.283"}],"container-title":["Therapeutics and Clinical Risk Management"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T01:32:29Z","timestamp":1683855149000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/skin-and-skin-structure-infections-treatment-with-newer-generation-flu-peer-reviewed-article-TCRM"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["10.2147\/tcrm.2007.3.2.309"],"URL":"https:\/\/doi.org\/10.2147\/tcrm.2007.3.2.309","relation":{},"ISSN":["1176-6336"],"issn-type":[{"value":"1176-6336","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}